Specifically, we focused on the effects of DDPi therapy on IL-1ß due to its important role as a pro-inflammatory signaling cytokine, a key factor in the pathogenesis and progression of atherosclerosis [30–34]. The gene discussed is IL1B; the disease is atherosclerosis.